Dendreon Pharmaceuticals Invests in Contract Manufacturing and Patient Services for Cell Therapy Partners

Dendreon Pharmaceuticals投资于细胞治疗合作伙伴的合同制造和患者服务

2021-06-16 07:00:12 BioSpace

本文共1178个字,阅读需3分钟

– Leader in the Commercial Delivery of Cell Therapies Offers Core Capabilities to Fill Expertise Gap in the Market – SEAL BEACH, Calif.--(BUSINESS WIRE)-- Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs. “Innovative cell therapies have the potential to change how we treat serious diseases, but there is currently insufficient capacity to meet anticipated industry demand,” said Jason O’Neill, Chief Executive Officer of Dendreon. “With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, we have invested in an offering that fills an immediate market need in this rapidly expanding field. This is a significant accomplishment for Dendreon and plays a key role in our future growth plans.” Dendreon is one of only four companies manufacturing cell therapies for commercial use in the United States and began investing in dedicated capacity for later-stage partner programs within its existing infrastructure in early 2021. The company’s 180,000+ square foot cGMP-compliant and FDA approved manufacturing facility in Seal Beach, CA will serve as the contract manufacturing services hub. Its Seattle facility will serve as the process development and manufacturing sciences center. “We are enabling the future of immunotherapy and supporting an unmet need in the market with immediate access to capacity and expertise,” said Maria Cho, Vice President of Business Development and Corporate Strategy. “We are looking to establish partnerships with biopharmaceutical companies developing CAR-Ts, autologous, or allogeneic cell therapies. Looking ahead, we plan to continue to leverage our core capabilities as a growth engine for our strategic partners and the industry as a whole.” For more information about Dendreon’s contract manufacturing services division, please visit https://www.dendreon.com/Partner-With-Us. About Dendreon Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells and has been prescribed to over 40,000 men with advanced prostate cancer in the U.S. since 2010. Dendreon is headquartered in Seal Beach, Calif. For more information, please visit www.dendreon.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005281/en/ Annalisa Ledonne annalisa.ledonne@Dendreon.com T +1.857.939.1991 Source: Dendreon Pharmaceuticals View this news release online at: http://www.businesswire.com/news/home/20210615005281/en
-细胞疗法商业交付的领导者提供核心能力以填补市场上的专业空白- 加州海尔比奇--(商业报道)--登德隆制药公司,一家商业阶段的生物制药公司和细胞免疫疗法发展的先驱,已经建立并投资于其新的合同制造和服务部门,以将晚期临床资产商业化。利用其广泛的制造、工艺开发和物流专业知识,Dendreon现在为合作伙伴计划提供复杂细胞疗法的端到端制造和病人物流服务。 Dendreon公司首席执行官Jason O'Neill说:“创新细胞疗法有可能改变我们治疗严重疾病的方式,但目前的能力不足以满足预期的行业需求。”“凭借在细胞治疗制造方面十多年的经验证明的专业知识和已建立的供应链和物流基础设施,我们投资于满足这一迅速扩大的领域的直接市场需求的产品。这是Dendreon公司的一项重大成就,在我们未来的增长计划中起着关键作用。“ Dendreon是美国仅有的四家为商业用途制造细胞疗法的公司之一,并于2021年初开始在其现有基础设施内投资后期合作伙伴项目的专用能力。该公司位于加利福尼亚州海豹滩的18万多平方英尺的cGMP合规和FDA批准的生产设施将作为合同制造服务中心。西雅图工厂将作为工艺开发和制造科学中心。 业务发展和公司战略副总裁Maria Cho说:“我们正在推动免疫疗法的未来,并通过立即获得能力和专业知识来支持市场上尚未满足的需求。“我们正在寻求与开发CAR-Ts、自体或异体细胞疗法的生物制药公司建立伙伴关系。展望未来,我们计划继续利用我们的核心能力,作为战略合作伙伴和整个行业的增长引擎。“ 欲了解更多有关Dendreon合同制造服务部门的信息,请访问https://www.dendreon.com/partner-with-us。 关于Dendreon Dendreon是一家商业阶段的生物制药公司和为细胞治疗市场提供制造服务的端到端供应商。Dendreon的旗舰产品Provenge®(sipuleucel-T)是FDA批准的第一种由患者自身免疫细胞制成的免疫疗法,自2010年以来,已为美国4万多名晚期前列腺癌患者开出处方。Dendreon公司总部设在加利福尼亚州海豹滩。欲了解更多信息,请访问www.dendreon.com。 在BusinessWire.com上查看源版本:https://www.businessWire.com/news/home/20210615005281/en/ 安娜利莎·莱顿 @dendreon.com Annalisa.ledonne@dendreon.com T+1.857.939.1991 来源:Dendreon Pharmaceuticals 请在以下网址联机查看此新闻稿: http://www.businesswire.com/news/home/20210615005281/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文